Humacyte, Inc. 8-K

What Happened Humacyte, Inc. (Nasdaq: HUMA) filed an 8-K on May 8, 2026 disclosing that Nasdaq notified the company its common stock’s bid price had closed below the $1.00 minimum for continued listing on the Nasdaq Global Select Market for the 30 consecutive business days ended May 1, 2026. Under Nasdaq Listing Rule 5810(c)(3)(A), Humacyte has an initial 180-calendar-day compliance period—until November 2, 2026—to regain compliance by achieving a closing bid price of $1.00 or more for at least 10 consecutive business days. The notice does not have any immediate effect on the listing or trading of the shares.

Key Details

• Nasdaq identified non-compliance under Nasdaq Listing Rule 5450(a)(1) for the 30 business days ended May 1, 2026.
• Compliance deadline (initial period): 180 calendar days, through November 2, 2026.
• Requirement to regain compliance: closing bid ≥ $1.00 per share for 10 consecutive business days.
• The company’s common stock continues to trade on the Nasdaq Global Select Market under the symbol "HUMA."

Why It Matters A Nasdaq deficiency notice signals a potential delisting risk if the share price does not recover within the required timeframe. For investors, this affects market confidence, liquidity, and could limit access to certain institutional buyers if not resolved. Humacyte stated it will monitor the stock price and consider options to achieve compliance; however, there is no assurance it will succeed. The filing also includes standard forward-looking statement cautions about uncertainty and risks.